Biblio

8 resultats trouvés
Filtres: Mot-clé is Checkpoint inhibitors  [Clear All Filters]
L
Manson G, Mear J-B, Herbaux C, Schiano J-M, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C et al..  2019.  Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. EUROPEAN JOURNAL OF CANCER. 115:47-56.
M
Zanella A, Doussot A, Puzenat E, Aubin F, Nardin C.  2020.  MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted? MELANOMA RESEARCH. 30:606-607.
N
Kroemer M., Turco C., Galaine J., Deschamps M., Limat S., Borg C..  2015.  New immunotherapeutic approaches in oncology and hematology. TRANSFUSION CLINIQUE ET BIOLOGIQUE. 22:132-140.
Ghiringhelli F.  2018.  Novel strategy in oncoimmunology. BULLETIN DU CANCER. 105:S101-S112.
Ghiringhelli F.  2018.  Novel strategy in oncoimmunology. BULLETIN DU CANCER. 105:S101-S112.
R
Aarnink A, Fumet JDavid, Favier L, Truntzer C, Ghiringhelli F.  2020.  Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 146:2699-2707.
Aarnink A, Fumet JDavid, Favier L, Truntzer C, Ghiringhelli F.  2020.  Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 146:2699-2707.
V
Deschenes-Simard X, Richard C, Galland L, Blais F, Desilets A, Malo J, Cvetkovic L, Belkaid W, Elkrief A, Gagne A et al..  2021.  Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. THROMBOSIS RESEARCH. 205:29-39.